Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if CBIO is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
25 top institutions tracked
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 27 days ago
Red flags: 14
80 filers reported a long position in CBIO for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| FMR LLC | $74.4M | 4.1M | Unchanged |
| BVF INC/IL | $49.5M | 2.7M | Unchanged |
| Fairmount Funds Management LLC | $49.5M | 2.7M | Unchanged |
| Venrock Adviser, LLC | $38.4M | 2.1M | Unchanged |
| Logos Global Management LP | $34.2M | 1.9M | +293.8% |
| FCPM III SERVICES B.V. | $30.2M | 1.7M | Unchanged |
| BALYASNY ASSET MANAGEMENT L.P. | $29.9M | 1.7M | +10.1% |
| Vestal Point Capital, LP | $29.3M | 1.6M | +8.7% |
| Opaleye Management Inc. | $23.7M | 1.3M | +0.5% |
| BlackRock, Inc. | $22.9M | 1.3M | +999% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.